This statistic depicts the total prescription drug revenue worldwide that is at risk due to patent expiration from 2010 to 2024. In 2022, the industry is expected to have 40 billion U.S. dollars in prescription drug sales worldwide at risk due to patent expiration. After the expiration of patent protection, other companies are allowed to make cheaper generics of the originally branded drug.
Patent expiration risks for total worldwide prescription drug revenue 2010-2024
Worldwide total prescription drug revenue at risk from patent expiration from 2010 to 2024 (in billion U.S. dollars)*
Basic Account
Get to know the platform
You only have access to basic statistics.
This statistic is not included in your account!
Premium Account
Your perfect start with Statista
- Instant access to 1m statistics
- Download in XLS, PDF & PNG format
- Detailed references
$59 / Month *
Corporate Account
Full access
Corporate solution including all features.
* All products require an annual contract.
Prices do not include sales tax.
Prices do not include sales tax.
Further Content: You might find this interesting as well
Statistics
- Peak sales per new pharmaceutical asset 2010-2018
- Orphan vs. non-orphan pipeline sales forecast worldwide 2019-2024
- Worldwide Rx drug sales excluding generics and orphan drugs 2002-2024
- Orphan vs. non-orphan drugs median cost per patient per year 2014-2018
- Worldwide share of orphan drug sales by therapy category without oncology 2024
- U.S. orphan drugs with patents and orphan drug exclusivity as of 2018
- U.S. orphan drugs with patents and orphan drug exclusivity as of 2018, by duration
- Orphan drug sales worldwide excluding oncology by therapy category 2024
- Top U.S. SNRIs based on revenue 2013
- Top U.S. market share of SNRIs based on revenue 2013
- Brazil: pharma industry market value 2008-2017
- Global pharmaceutical industry by growth rate in wages and salaries 2006-2014
- Digital health strategy priorities for pharma companies 2013
- Pharma sales as share of health spending in Latin America by major country 2014
- Italy: value of investments in R&D of biotech pharma companies 2014-2017
- Latin America: pen needles revenue 2018-2023
- Nuclear medicine/radiopharmaceuticals market revenue worldwide 2017-2027
- Global industrial microbiology market share by application area 2016 & 2025
- Sales share of the leading first aid brands in the U.S. 2016
- Share of laboratory researchers that ever sustained a personal injury at work 2012
Further related statistics
Evaluate. (June 4, 2019). Worldwide total prescription drug revenue at risk from patent expiration from 2010 to 2024 (in billion U.S. dollars)* [Graph]. In Statista. Retrieved December 10, 2019, from https://www.statista.com/statistics/309404/global-total-prescription-drug-revenue-at-risk-from-patent-expiration/
Evaluate. "Worldwide total prescription drug revenue at risk from patent expiration from 2010 to 2024 (in billion U.S. dollars)*." Chart. June 4, 2019. Statista. Accessed December 10, 2019. https://www.statista.com/statistics/309404/global-total-prescription-drug-revenue-at-risk-from-patent-expiration/
Evaluate. (2019). Worldwide total prescription drug revenue at risk from patent expiration from 2010 to 2024 (in billion U.S. dollars)*. Statista. Statista Inc.. Accessed: December 10, 2019. https://www.statista.com/statistics/309404/global-total-prescription-drug-revenue-at-risk-from-patent-expiration/
Evaluate. "Worldwide Total Prescription Drug Revenue at Risk from Patent Expiration from 2010 to 2024 (in Billion U.S. Dollars)*." Statista, Statista Inc., 4 Jun 2019, https://www.statista.com/statistics/309404/global-total-prescription-drug-revenue-at-risk-from-patent-expiration/
Evaluate, Worldwide total prescription drug revenue at risk from patent expiration from 2010 to 2024 (in billion U.S. dollars)* Statista, https://www.statista.com/statistics/309404/global-total-prescription-drug-revenue-at-risk-from-patent-expiration/ (last visited December 10, 2019)